Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVERTURE: EYC-0305 in Neovascular Age-Related Macular Degeneration
NCT07587515Phase 2Recruiting
- Sponsor
- Eyconis
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of EYC-0305 in neovascular age-related macular degeneration (NVAMD), sponsored by Eyconis. Started May 2026; status: recruiting.
02
Drugs
EYC-0305
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07587515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587515.